During the European Society of Medical Oncology (ESMO) Congress, to be held from September 27th to October 1st in Barcelona, the recent results of the lurbinectedin trial for the treatment of progressive malignant pleural mesothelioma, carried out by SAKK in collaboration with PharmaMar, will be presented.
- Lurbinectedin data for the treatment of progressive malignant pleural mesothelioma will be presented in an oral session at the international congress to be held this month in Barcelona.
- Data on new combinations of trabectedin for the treatment of soft tissue sarcoma, ovarian cancer and different solid tumors will also be revealed.
Madrid, September 23rd, 2019.- During the European Society of Medical Oncology (ESMO) Congress, to be held from September 27th to October 1st in Barcelona, the recent results of the lurbinectedin trial for the treatment of progressive malignant pleural mesothelioma, carried out by SAKK (Swiss Group for Clinical Cancer Research) in collaboration with PharmaMar (MSE:PHM), will be presented.
The oral presentation will be entitled “SAKK 17/16: Lurbinectedin as second or third line palliative chemotherapy in pleural malignant mesothelioma (MPM): A multi-center, single-arm Phase II trial”. During this conference, the primary results will be shown from a single arm, multicenter, Phase II trial, which has enrolled 42 patients with progressive malignant pleural mesothelioma, which met its primary endpoint of PFS at 12 weeks.
Malignant mesothelioma is a rare tumor, arising from the mesothelial cells of the pleural, peritoneal or pericardial lining, and is often associated with exposure to asbestos, usually with a very poor prognosis at the time of diagnosis, being pleural mesothelioma the most frequent location. There is currently no cure for most malignant mesotheliomas. Therefore, the goal of current cancer treatments (surgery, radiation therapy, and chemotherapy) is to reduce or eliminate symptoms, as well as to prolong progression-free survival (PFS) and/or overall survival (OS). It is estimated that the incidence of this type of cancer may increase in the coming years, after the exposure to asbestos. It usually takes a long time before a malignant mesothelioma forms.
Trabectedin
In addition, the data obtained in several clinical studies carried out with trabectedin, evaluating new combinations of trabectedin for the treatment of soft tissue sarcoma, ovarian cancer and different solid tumors will be presented. Among them, data from a multicenter Phase II study of trabectedin in combination with a low dose of radiotherapy conducted by Sarcoma Research Groups in Spain, France and Italy, will be presented.
The studies presented at the ESMO 2019 congress are available at: https://cslide.ctimeetingtech.
Highlighted studies at ESMO 2019
Lurbinectedin
- Proffered Paper 2 – Non-metastatic NSCLC and other thoracic malignancies (mesothelioma and thymic carcinoma)
Oral presentation - 30.09.2019, 10:15 - 11:45, Pamplona Auditorium (Hall 2)
Autor principal: Yannis Metaxas (Chur, Switzerland) - Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors
Poster Display session - 28.09.2019, 12:00 - 13:00, Poster Area (Hall 4)
Autor principal: Santiago Ponce
Yondelis® (trabectedin)
- Trabectedin with concurrent low-dose of radiation therapy for metastatic soft tissue sarcomas: A phase II trial of Spanish, French and Italian sarcoma groups
Poster Discussion – Sarcoma. 28.09.2019, 15:00 - 16:00, en Malaga Auditorium (Hall 5)
Autor principal: J Martin-Broto (Sevilla)
- Inhibition of mTOR signaling enhances Trabectedin activity in Soft Tissue Sarcoma
Poster Display session. 28.09.2019, 12:00 - 13:00, Poster Area (Hall 4).
Autor principal: David S. Moura, PhD.
- Randomized Phase II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies
Poster - 30.09.2019, 12:00 - 13:00, en el Hall A3 - Poster Area (Hall 4)
Autor principal: S Christoph E. Heilig, Germany.
- Impact of prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer (ROC): Sub-group analysis from a randomized, open-label study comparing trabectedin (T) and PLD versus PLD alone in ROC (ET743-OVC-3006)
Poster - 29.09.2019, 12:00 - 13:00, Poster Area (Hall 4).
Autor principal: Bradley J Monk, USA.
Legal warning
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
About PharmaMar
Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.
PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: lurbinectedin (PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.
About lurbinectedin
Lurbinectedin (PM1183) is a synthetic compound currently under clinical investigation. It is a selective inhibitor of the oncogenic transcription programs on which many tumors are particularly dependent. Together with its effect on cancer cells, lurbinectedin inhibits oncogenic transcription in tumor-associated macrophages, downregulating the production of cytokines that are essential for the growth of the tumor. Transcriptional addiction is an acknowledged target in those diseases, many of them lacking other actionable targets.
About Yondelis®
Yondelis® (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from Ecteinascidia turbinata, a type of sea squirt. Yondelis® exerts its anticancer effects primarily by inhibiting active transcription, a type of gene expression on which proliferating cancer cells are particularly dependent.
Media Contact:
Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000
Investor Relations:
José Luis Moreno Martínez-Losa – Capital Markets & Investor Relations Director
investorrelations@pharmamar.
Phone: +34 914444500
